A new class of drug called siRNA, a cousin of mRNA, can enter cells and stop a specific gene from producing a harmful protein. This enables highly targeted treatments, such as new drugs that reduce a type of cholesterol by over 95% with a single, long-lasting injection.

After decades of work, small interfering RNA (siRNA) has overcome delivery challenges to become a mature, "de-risked" platform, primarily for liver-directed targets. This now enables powerful medicines like a once-yearly injection for high cholesterol, representing a major public health breakthrough.

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

The company's therapy uses transient engineering with a single mRNA strand to deliver both anti-inflammatory and anti-fibrotic payloads into a patient's own macrophages. This enhances the cells' natural healing abilities, aiming to reduce inflammation and resolve fibrotic scars to allow organs like the liver to regenerate.

The industry is on the cusp of a seismic therapeutic shift. Major Phase 3 readouts for siRNA/ASO in common diseases are expected in the next year. Simultaneously, in vivo CAR-T for autoimmunity represents a move from treating symptoms to potentially curing diseases, a true revolutionary step.

The next leap in medicine isn't just delivering a payload but programming it with conditional logic. Radar Therapeutics engineers mRNA to act like software with "if/and/or" commands. This allows the therapy to sense its cellular environment and activate only in the right context, moving beyond a simple "execute" function.

Thalia's strategy isn't to compete with established players on single-target assets. Instead, it aims to create a new category with bispecific siRNAs that target multiple disease pathways simultaneously, combined with novel delivery systems to reach tissues beyond the liver.

Voyager CEO Al Sandrock explains their AAV capsids are engineered to be so potent at crossing the blood-brain barrier that doses can be an order of magnitude lower than standard. Crucially, the capsids are also designed to *avoid* the liver, directly addressing the toxicity issues that have plagued the field.

CEO Lance Baldo suggests that gene therapy in the eye is uniquely positioned for success. As an encapsulated organ with "immune privilege," the eye reduces risks like hepatotoxicity seen in systemic therapies. This creates a safer environment to generate learnings that can then be applied to advance gene therapies for other organs.